Gilles Avenard

Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.

GOUR Medical is a pharmaceutical development company dedicated to the commercialization of veterinary drugs, specializing in mature pets. The company was established in July 2014 and is based in Paris, France GOUR Medical’s main idea is to allow mature pets to benefit from the progress of human medicine, giving them the opportunity to live longer and enjoy healthier lives. Since its creation, a team of recognized experts from the animal health industry has joined GOUR Medical to create an ecosystem able to identify products derived from technologies originally developed for humans. Thanks to its leading know-how in identifying and selecting drug candidates and maximizing the clinical and commercial potential of these products, GOUR Medical has been able to convince industry leaders, in the first instance Bio-pharmaceutical in human health, to entrust the development of their products for animal health use through exclusive and worldwide licenses.

Created in 2013, CleveXel Pharma is a pharmaceutical company with an innovative business model based on maximizing the marketing potential of disruptive molecules in exchange for a stake in the partner's equity or for the gradual purchase of a license.

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory. The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

InnaVirVax is a French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and cancer therapies. InnaVirVax is developing product candidates resulting from a beakthrough discovery, made at Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes (CD4) in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover, InnaVirVax has an AIDS prognostic test in its R&D portfolio. Lastly, InnaVirVax is developing an innovative cancer biotherapy. The discovery has identified that a dysregulation of the innate immune system is responsible for the loss of CD4 in HIV-infected patients. The understanding of this dysregulation (resulting in the presence at the surface of the CD4 of a NK cell ligand, making CD4 sensitive to NK-mediated cell lysis) has allowed InnaVirVax to design a therapeutic vaccine for HIV infection that has been successfully tested in non human primates and which has now recieved the authorization to run a first in man study. In addition InnaVirVax is developing an innovative cancer therapy.

Aquitaine Science Transfert is the Nouvelle Aquitaine TTO (Technology Transfer Office). Our mission is to generate economic and social value out of public research, whether it deals with startups creation or patent licensing. Thanks to all researchers in Aquitaine region, we cover all fields of science : health and medical, aeronautics, space and defence, green techs, energy, utilities, engineers science, social and human sciences, etc. We represent our shareholders : University of Bordeaux, Bordeaux INP (publicengineers school), the National Center for Scientific Research (CNRS), the French National Institute of Health and Medical Research (INSERM), Pau and Pays of Adour University (UPPA), ESTIA, Bergonié Institute, Bordeaux Universitary Hospital Center (CHU Bordeaux), Bordeaux IEP, Bordeaux Montaigne University and Bordeaux Sciences Agro (BSA). Since our inception, we have helped incorporate 13 startups and put 7 products & services on the market, signed 37 license agreements with private companies, patented 243 technologies and softwares, and signed 2 120 research contracts on behalf of our shareholder establishments. On the whole, we have invested M€ 10.4 in the maturation of technologies and M€ 2.8 in the IP portfolio of our shareholder establishments.

Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.

GOUR Medical is a pharmaceutical development company dedicated to the commercialization of veterinary drugs, specializing in mature pets. The company was established in July 2014 and is based in Paris, France GOUR Medical’s main idea is to allow mature pets to benefit from the progress of human medicine, giving them the opportunity to live longer and enjoy healthier lives. Since its creation, a team of recognized experts from the animal health industry has joined GOUR Medical to create an ecosystem able to identify products derived from technologies originally developed for humans. Thanks to its leading know-how in identifying and selecting drug candidates and maximizing the clinical and commercial potential of these products, GOUR Medical has been able to convince industry leaders, in the first instance Bio-pharmaceutical in human health, to entrust the development of their products for animal health use through exclusive and worldwide licenses.

Created in 2013, CleveXel Pharma is a pharmaceutical company with an innovative business model based on maximizing the marketing potential of disruptive molecules in exchange for a stake in the partner's equity or for the gradual purchase of a license.